Global Orthobiologics Market Size, Status and Forecast By Top Players - Medtronic Plc (Ireland); Zimmer Biomet Holdings, Inc. (US)

1
Global Orthobiologics Market Growth is set to be
driven by the Increasing Number of People
Suffering from Arthritis and Other Spine-Related
Disorders
2

• Orthobiologics uses biomaterials and cell-based
  therapies to heal musculoskeletal injuries
  quickly and support tissue healing and
  restoration through their regenerative potential.
  These products are derived from components that
  are naturally present in the body and interact
  dynamically with the musculoskeletal system to
  facilitate the healing of bone, cartilage,
  ligament, and diseased or injured meniscus
  tendons.
• The Global Orthobiologics Market valued at 5.4
  billion (2021) is set to witness a growth rate of
  7 in the next 5 years. Increasing geriatric and
  obese populations globally, an increase in the
  number of people suffering arthritis and other
  spine-related disorders, an increase in patient
  preference for minimally invasive procedures, and
  mechanical advancements in biomaterials are some
  of the main reasons propelling the global
  orthobiologics market.
• Technological advancements in Orthobiologics
  Market to fuel its Global Market demand
• The development of effective products with
  enhanced patient healing capacities and expanded
  applications, among other things, has been made
  possible by continuous advancements in
  orthobiologics. As a result, key companies are
  constantly focusing on investing in research
  activities for the development of new products
  and increasing their geographic reach to
  strengthen their positions in the orthobiologics
  market. Such advances tend to provide
  manufacturers a competitive edge.
• Below is a list of a few technological
  developments
• In June 2022, Istos Biologics launched the Influx
  Fibrant line of 100 cortical allograft products
  featuring a patented technology from TheraCell
  and designed to advance patient healing
• In March 2022, SeaSpine launched new
  orthobiologic products- NorthStar cervical facet
  fusion and Flash navigation lumbar facet fusion,
  with an aim to streamline reproducible procedural
  workflow while maximizing the area for fusion
• In September 2020, Cerapedics received approval
  for its i-FACTOR Matrix bone graft from Health
  Canada. This next-generation bone graft is based
  on P15 osteogenic cell-binding peptide that
  supports bone growth through cell attraction,
  attachment, and activation

3

• Explore Premium Report on Orthobiologics Market
  _at_ https//meditechinsights.com/orthobiologics-mark
  et/
• Key Growth Strategies Adopted by Leading Market
  Players in Orthobiologics Market
• Leading Market players operating in the
  orthobiologics market have accepted acquisition
  and partnership as key growth strategy to
  increase their product offerings, improve their
  geographic presence distribution capabilities,
  and to co-develop advanced products.
• Some of these developments are listed below
• In August 2022, Orthofix Medical Inc. entered in
  a strategic partnership with CGBio, a synthetic
  bone grafts developer, to co-develop and
  commercialize Novosis recombinant human bone
  morphogenetic protein-2 (rhBMP-2) bone growth
  materials and other tissue regenerative solutions
  for the Canadian and US markets
• In July 2021, Celularity Inc. and Arthrex,
  Inc. entered into a supply and distribution
  agreement for the distribution and
  commercialization of multiple products including
  placental-derived biomaterial products from
  Celularity for orthopaedics and sport medicine in
  the US
• In March 2021, SeaSpine Holdings
  Corporation entered in an agreement to acquire 7D
  Surgical, Inc., a Canada-based medical device
  company. This acquisition was aimed at combining
  spinal implant and orthobiologics portfolios to
  advance spine surgery
• Irrespective of the challenges such as
  unfavorable reimbursement scenario and pricing
  pressure on market players, the global
  orthobiologics market is expanding and is
  anticipated to gain further momentum in the
  coming years due to a strong emphasis on spinal
  fusion segment, focus on demineralized bone
  putties with excipients, growing usage of
  viscosupplements, and innovations addressing the
  entire procedure, among others.

4
For instance, during the forecast period,
advances in hyaluronic acid-based therapies,
rising prevalence of lifestyle-induced disorders,
high efficacy in delaying total knee replacement
procedures, and growing preference for
non-surgical treatments for osteoarthritis are
expected to drive the viscosupplements segment.
Furthermore, conventional techniques such as
autograft and allograft are difficult to manage,
painful for the patient, have fairly contrasting
outcomes, and may require repeat surgeries.
Hence, an easier-to-use solution is likely to be
accepted by doctors and healthcare providers
which has greater success rate from a medical and
financial standpoint, providing opportunity for
market players in this space. Competitive
Landscape Analysis of Orthobiologics Market The
orthobiologics market is marked by the presence
of key players such as Medtronic Plc (Ireland)
Zimmer Biomet Holdings, Inc. (US) Arthrex, Inc.
(US) Bioventus (US) DePuy Synthes (Johnson
Johnson Services, Inc.) (US) Stryker Corporation
(US) MTF Biologics (US) and others. For More
Detailed Insights, Contact Us _at_ https//meditechin
sights.com/contact-us/ About Medi-Tech
Insights Medi-Tech Insights is a
healthcare-focused business research insights
firm. Our clients include Fortune 500 companies,
blue-chip investors hyper-growth start-ups. We
have completed 100 projects in Digital Health,
Healthcare IT, Medical Technology, Medical
Devices Pharma Services. Contact Ruta
Halde Associate, Medi-Tech Insights 32 498 86 80
79 info_at_meditechinsights.com